Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* More than 18 years of age.~* STEMI less than 12 hours from onset of pain. STEMI defined as as ST-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mV in V4 - V6 or limb leads II, III and aVF, or \>0.2 mV in lead V1 - V3.~* TIMI 0-1 in infarct related artery.~* Oral and written informed consent.~Exclusion Criteria:~* Multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery.~* Previous myocardial infarction.~* Stent trombosis.~* Previous CABG.~* Less than TIMI 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment.~* Renal insufficiency (creatinin \>200).~* Pregnancy or lactation.~* Diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l).~* Pancreatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: ACTIVE_COMPARATOR): 25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
- Saline (Type: PLACEBO_COMPARATOR): Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).